Trial Profile
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VISUAL III
- Sponsors Abbott Healthcare; AbbVie
- 24 Oct 2018 Interim results data cut off (31 oct 2016) of 0 to 78 weeks assessing efficacy of adalimumab by immunosuppressant use in non-infectious intermediate, posterior, or panuveitis patients, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 16 Jun 2018 Long-term safety and efficacy results (n=371; interim data cut off 31 Oct 2016) presented at the 19th Annual Congress of the European League Against Rheumatism.
- 16 Jun 2018 Results (n=371) evaluating long term safety and efficacy presented at the 19th Annual Congress of the European League Against Rheumatism